<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002128</url>
  </required_header>
  <id_info>
    <org_study_id>232A</org_study_id>
    <secondary_id>GS-93-401</secondary_id>
    <nct_id>NCT00002128</nct_id>
  </id_info>
  <brief_title>Phase I Study of the Safety, Tolerance, and Pharmacokinetics of 9-[2-(Bispivaloyloxymethyl)Phosphonylmethoxyethyl]Adenine (Bis-POM PMEA; Adefovir Dipivoxil) in HIV-Infected Patients</brief_title>
  <official_title>Phase I Study of the Safety, Tolerance, and Pharmacokinetics of 9-[2-(Bispivaloyloxymethyl)Phosphonylmethoxyethyl]Adenine (Bis-POM PMEA; Adefovir Dipivoxil) in HIV-Infected Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To study the safety, tolerance, and pharmacokinetics of a single dose of bis-POM PMEA
      (adefovir dipivoxil) when administered by the oral route in patients with HIV infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Five patients are entered at each of three dose levels of bis-POM PMEA administered orally in
      a single dose.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>15</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adefovir dipivoxil</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        Concurrent Medication:

        Allowed:

          -  AZT, ddI, or ddC (provided patient has been on a stable regimen for at least 4 weeks
             prior to study entry).

          -  Prophylactic aerosolized pentamidine, fluconazole, ketoconazole,
             trimethoprim/sulfamethoxazole, or dapsone (provided patient has been on a stable
             regimen for at least 4 weeks prior to study entry).

        Patients must have:

          -  Documented HIV infection or diagnosis of AIDS.

          -  Life expectancy of at least 3 months.

        Prior Medication:

        Allowed:

          -  Prior AZT, ddI, or ddC.

          -  Prophylactic aerosolized pentamidine, fluconazole, ketoconazole,
             trimethoprim/sulfamethoxazole, or dapsone.

        Exclusion Criteria

        Co-existing Condition:

        Patients with the following symptoms or conditions are excluded:

          -  Active, serious infections (other than HIV infections) that require parenteral
             antibiotic therapy.

          -  Clinically significant cardiac disease, including symptoms of ischemia, congestive
             heart failure, or arrhythmia.

          -  Gastrointestinal malabsorption syndrome or inability to receive oral medication.

        Concurrent Medication:

        Excluded:

          -  Diuretics.

          -  Amphotericin B.

          -  Aminoglycoside antibiotics.

          -  Parenteral antibiotics.

          -  Other nephrotoxic agents.

          -  Other investigational agents.

          -  Non-steroidal anti-inflammatory drugs.

          -  Aspirin.

        Prior Medication:

        Excluded within 2 weeks prior to study entry:

          -  Diuretics.

          -  Amphotericin B.

          -  Aminoglycoside antibiotics.

          -  Parenteral antibiotics.

          -  Other nephrotoxic agents.

          -  Other investigational agents.

        Excluded within 3 days prior to study entry:

          -  Non-steroidal anti-inflammatory drugs.

          -  Aspirin. Active substance abuse (including alcohol or drug abuse).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Johns Hopkins Univ</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Cundy KC, Barditch-Crovo P, Walker RE, Collier AC, Ebeling D, Toole J, Jaffe HS. Clinical pharmacokinetics of adefovir in human immunodeficiency virus type 1-infected patients. Antimicrob Agents Chemother. 1995 Nov;39(11):2401-5.</citation>
    <PMID>8585716</PMID>
  </reference>
  <verification_date>July 1994</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>AIDS-Related Complex</keyword>
  <keyword>Antiviral Agents</keyword>
  <keyword>Adenine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adefovir</mesh_term>
    <mesh_term>Adefovir dipivoxil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

